
Over the last 7 days, the Life Sciences industry has risen 3.8%, driven by gains from EirGenix of 7.8%. During this same period, the Creative Life Science underperformed, falling 7.1%. Overall in the last year, the industry is flat.
Has the Taiwanese Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 06 Jul 2026 | NT$32.5b | NT$2.7b | -NT$746,869,000.00 | 19x | -43.5x | 12.3x |
| Wed, 03 Jun 2026 | NT$32.7b | NT$2.7b | -NT$746,869,000.00 | 21.2x | -43.8x | 12.3x |
| Fri, 01 May 2026 | NT$39.0b | NT$2.5b | -NT$764,028,000.00 | 22.1x | -51x | 15.5x |
| Sun, 29 Mar 2026 | NT$31.5b | NT$2.5b | -NT$750,275,000.00 | 21.1x | -42x | 12.6x |
| Tue, 24 Feb 2026 | NT$33.3b | NT$2.4b | -NT$689,929,000.00 | 23.3x | -48.3x | 13.7x |
| Thu, 22 Jan 2026 | NT$34.4b | NT$2.4b | -NT$689,929,000.00 | 24.7x | -49.8x | 14.1x |
| Sat, 20 Dec 2025 | NT$34.8b | NT$2.4b | -NT$670,921,000.00 | 23.9x | -51.9x | 14.2x |
| Mon, 17 Nov 2025 | NT$40.2b | NT$2.5b | -NT$679,280,000.00 | 19.4x | -59.2x | 16.4x |
| Wed, 15 Oct 2025 | NT$38.8b | NT$2.5b | -NT$870,437,000.00 | 18.9x | -44.6x | 15.8x |
| Fri, 12 Sep 2025 | NT$35.0b | NT$2.5b | -NT$819,216,000.00 | 20.2x | -42.7x | 14.3x |
| Sun, 10 Aug 2025 | NT$33.2b | NT$2.5b | -NT$600,003,000.00 | 20.6x | -55.4x | 13.5x |
| Tue, 08 Jul 2025 | NT$33.2b | NT$2.5b | -NT$600,003,000.00 | 22.7x | -55.3x | 13.5x |
| Thu, 05 Jun 2025 | NT$33.6b | NT$2.5b | -NT$600,003,000.00 | 22.3x | -56x | 13.6x |
| Sat, 03 May 2025 | NT$31.9b | NT$2.5b | -NT$540,128,000.00 | 23.9x | -59x | 13x |
| Mon, 31 Mar 2025 | NT$36.4b | NT$2.4b | -NT$560,979,000.00 | 28.9x | -64.8x | 15.1x |
| Wed, 26 Feb 2025 | NT$37.0b | NT$2.6b | -NT$854,432,000.00 | 24.1x | -43.4x | 14.5x |
| Fri, 24 Jan 2025 | NT$36.8b | NT$2.6b | -NT$854,432,000.00 | 23.5x | -43.1x | 14.4x |
| Sun, 22 Dec 2024 | NT$34.3b | NT$2.6b | -NT$854,432,000.00 | 24.5x | -40.2x | 13.4x |
| Tue, 19 Nov 2024 | NT$40.2b | NT$2.6b | -NT$847,398,000.00 | 23.7x | -47.5x | 15.7x |
| Thu, 17 Oct 2024 | NT$40.7b | NT$2.3b | -NT$836,610,000.00 | 22.6x | -48.6x | 17.9x |
| Sat, 14 Sep 2024 | NT$40.3b | NT$2.3b | -NT$836,610,000.00 | 21.7x | -48.2x | 17.7x |
| Mon, 12 Aug 2024 | NT$39.3b | NT$2.1b | -NT$791,513,000.00 | 27.9x | -49.7x | 18.5x |
| Wed, 10 Jul 2024 | NT$44.1b | NT$2.1b | -NT$797,765,000.00 | 33.7x | -55.3x | 20.7x |
| Fri, 07 Jun 2024 | NT$40.3b | NT$2.1b | -NT$797,765,000.00 | 32.7x | -50.5x | 18.9x |
| Sun, 05 May 2024 | NT$39.8b | NT$2.1b | -NT$914,899,000.00 | 32.4x | -43.5x | 18.8x |
| Tue, 02 Apr 2024 | NT$40.7b | NT$2.1b | -NT$903,875,000.00 | 31.9x | -45x | 19.3x |
| Thu, 29 Feb 2024 | NT$44.0b | NT$2.1b | -NT$610,218,000.00 | 33.5x | -72x | 21.2x |
| Sat, 27 Jan 2024 | NT$44.3b | NT$2.1b | -NT$610,218,000.00 | 33.1x | -72.6x | 21.3x |
| Mon, 25 Dec 2023 | NT$47.2b | NT$2.1b | -NT$610,218,000.00 | 33.5x | -77.3x | 22.7x |
| Wed, 22 Nov 2023 | NT$47.8b | NT$2.1b | -NT$609,632,000.00 | 31.1x | -78.5x | 23x |
| Fri, 20 Oct 2023 | NT$46.4b | NT$2.2b | -NT$497,769,000.00 | 31x | -93.3x | 20.9x |
| Sun, 17 Sep 2023 | NT$44.1b | NT$2.2b | -NT$497,769,000.00 | 31x | -88.5x | 19.8x |
| Tue, 15 Aug 2023 | NT$42.7b | NT$2.2b | -NT$491,561,000.00 | 39.9x | -86.8x | 19.1x |
| Thu, 13 Jul 2023 | NT$47.7b | NT$2.5b | -NT$274,767,000.00 | 42.8x | -173.7x | 19.5x |
-173.7x
Which industries have driven the changes within the Taiwanese Healthcare industry?
| TW Market | 5.10% | |
| Healthcare | 9.27% | |
| Life Sciences | 3.84% | |
| Clinical Research and Equipment | 3.84% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6589 EirGenix | NT$51.40 | 6.6% +NT$969.2m | -16.4% | PS13.8x | |
| 6986 HeXun Biosciences | NT$51.10 | 10.8% +NT$230.0m | -29.6% | PE21x | |
| 6848 RBC Bioscience | NT$23.90 | 18.0% +NT$52.1m | 43.3% | PE14.5x | |
| 6939 TFBS Bioscience | NT$20.70 | 5.1% +NT$34.9m | -5.9% | n/a | |
| 6661 Welgene BiotechLtd | NT$18.55 | 8.5% +NT$33.8m | -7.2% | PS1.1x |